SBC Medical Announces Research Presentations at International Medical Conference “AMWC Japan 2026” Held in September 2026

Dr. Nishikawa of Shonan Beauty Clinic and Dr. Hayashi of SBC Skin Clinic share insights on Japanese and Korean beauty perceptions and injectable treatments

IRVINE, Calif. --SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced that Dr. Ayaka Nishikawa, Chief Director of Dermatology at Shonan Beauty Clinic, and Dr. Atsushi Hayashi, Director of SBC Skin Clinic Gotanda, clinics that receive management support from the Company, presented research findings at the international medical conference “AMWC Japan 2026,” held at The Prince Tower Tokyo on September 12 and 13, 2026.

“AMWC Japan” is the Japanese edition of AMWC (Aesthetic & Anti-Aging Medicine World Congress), one of the world’s largest congresses on aesthetic and anti-aging medicine, based in Monaco. It brings together specialists and researchers from around the world to share cutting-edge insights in fields such as aesthetic healthcare, dermatology, and regenerative medicine, fostering active academic exchange. “AMWC Japan 2026,” the largest edition to date, featured more than 120 speakers from 38 countries across five lecture halls, with numerous sessions including presentations and discussions.

Dr. Nishikawa took part in a discussion comparing perceptions of beauty in Japan and South Korea. Drawing on the results of a customer survey, she explained the importance of providing the most suitable treatment in line with customers’ increasingly diverse values and needs, attracting strong interest from participants. She also shared extensive clinical insights on injectable treatments, as represented by REJURAN injections, in a presentation titled “DOT™ PN in Aesthetic Practice: Clinical Considerations and Case-Based Insights.”

*Polynucleotides (PN): High-molecular-weight components derived from salmon DNA. With a viscous, three-dimensional structure, they are thought to act as a scaffold that supports tissue within the skin, and are used in injectable treatments aimed at improving skin texture and firmness.

Dr. Hayashi delivered a presentation titled “Two Elements That Complement Blind Manipulation in Injectable Treatment of Tear Troughs and Eye Bags.” He explained practical approaches, grounded in anatomical knowledge, for improving the precision and safety of non-surgical injectable treatments around the eyes, and engaged in active discussions with participants.

As technological innovation continues to accelerate in the field of aesthetic healthcare, the importance of knowledge sharing and academic collaboration, beyond the clinical setting alone, has grown considerably. Meeting the increasingly diverse needs of customers requires not only the adoption of advanced techniques, but also broad perspectives and flexible thinking. SBC Medical remains committed to advancing cutting-edge initiatives through academic activities and international exchanges with research institutions, and to upholding the safety, transparency, and enduring value of aesthetic healthcare.

Overview of “AMWC Japan 2026”
Venue: The Prince Tower Tokyo (Tokyo, Japan)
Dates: September 12 (Sat) and 13 (Sun), 2026
Official website: https://www.amwc-japan.com/

Presentation Titles
Dr. Ayaka Nishikawa (Chief Director of Dermatology, Shonan Beauty Clinic)
・“J Beauty vs. K Beauty: Differences in Trends, Techniques, and Patient Needs” (discussion)
・“DOT™ PN in Aesthetic Practice: Clinical Considerations and Case-Based Insights”

Dr. Atsushi Hayashi (Director, SBC Skin Clinic Gotanda)
・“Two Elements That Complement Blind Manipulation in Injectable Treatment of Tear Troughs and Eye Bags”

About SBC Medical Group Holdings Incorporated
SBC Medical is a Medical Services Organization providing management support across a wide range of healthcare fields, including advanced aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, hair loss treatment (AGA), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose “Contributing to the well-being of people around the world through medical innovation,” SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.

For more information, visit https://sbc-holdings.com
For more insights and updates from SBC Medical, follow us on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company’s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company’s control. These forward-looking statements reflect the Company’s current views with respect to, among other things, the Company’s plans and strategies for service expansion; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” “targets” or “hopes” or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading “Risk Factors” and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.

Contacts
Hikaru Fukui / Head of IR Department; E-mail: ir@sbc-holdings.com
Akiko Wakiyama / Chief Public Relations Officer; E-mail: pr@sbc.or.jp